Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
JE Chaft, A Rimner, W Weder, CG Azzoli… - Nature reviews Clinical …, 2021 - nature.com
The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary
discussions of surgical resectability and medical operability determine the modality of …
discussions of surgical resectability and medical operability determine the modality of …
Lung cancer: Biology and treatment options
H Lemjabbar-Alaoui, OUI Hassan, YW Yang… - … et Biophysica Acta (BBA …, 2015 - Elsevier
Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of …
M O'Brien, L Paz-Ares, S Marreaud, U Dafni… - The Lancet …, 2022 - thelancet.com
Background Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer
(NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage …
(NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage …
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 …
C Le Pechoux, N Pourel, F Barlesi, D Lerouge… - The Lancet …, 2022 - thelancet.com
Background In patients with non-small-cell lung cancer (NSCLC), the use of postoperative
radiotherapy (PORT) has been controversial since 1998, because of one meta-analysis …
radiotherapy (PORT) has been controversial since 1998, because of one meta-analysis …
Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical …
JA Howington, MG Blum, AC Chang, AA Balekian… - Chest, 2013 - Elsevier
Background The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients
with good or low surgical risk is primarily surgical resection. However, this area is …
with good or low surgical risk is primarily surgical resection. However, this area is …
Non-small-cell lung cancer
C Gridelli, A Rossi, DP Carbone, J Guarize… - Nature reviews Disease …, 2015 - nature.com
Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label …
WZ Zhong, Q Wang, WM Mao, ST Xu, L Wu… - The Lancet …, 2018 - thelancet.com
Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
J He, C Su, W Liang, S Xu, L Wu, X Fu… - The Lancet …, 2021 - thelancet.com
Background Icotinib has provided survival benefits for patients with advanced, epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We aimed to …
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We aimed to …
Management of non-small-cell lung cancer: recent developments
Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide.
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …